Your shopping cart is currently empty

LY456236 free base is a selective, non-competitive, orally active antagonist of the glutamate receptor 1 (mGlu1), effectively inhibiting phosphoinositide hydrolysis with an IC50 of 0.145 μM. Additionally, it inhibits EGFR with an IC50 of 0.918 μM. By suppressing the MAPK pathway, LY456236 free base blocks cell proliferation and counters the anti-apoptotic effects of DHPG. This compound is useful for seizure research.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | LY456236 free base is a selective, non-competitive, orally active antagonist of the glutamate receptor 1 (mGlu1), effectively inhibiting phosphoinositide hydrolysis with an IC50 of 0.145 μM. Additionally, it inhibits EGFR with an IC50 of 0.918 μM. By suppressing the MAPK pathway, LY456236 free base blocks cell proliferation and counters the anti-apoptotic effects of DHPG. This compound is useful for seizure research. |
| Molecular Weight | 281.32 |
| Formula | C16H15N3O2 |
| Cas No. | 338738-57-1 |
| Smiles | N=1C=NC(NC2=CC=C(OC)C=C2)=C3C=C(OC)C=CC13 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.